医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

INVESTOR ALERT: Investigation of USANA Health Sciences Inc. Announced by Glancy Binkow & Goldberg LLP

2014年07月24日 AM04:32
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of USANA Health Sciences Inc. (“USANA” or the “Company”) (NYSE:USNA) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning USANA’s business and operations.

Please contact us at (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

USANA develops, manufactures and sells nutritional and personal care products focusing on chronic degenerative disease worldwide. The investigation is related to allegations that the Company may have made false and misleading disclosures concerning its operations, true financial condition, and financial prospects, and that the Company has engaged in widespread, illegal multi-level marketing operations in China.

If you purchased USANA shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

CONTACT

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg,
888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表